Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is venture capital a necessity for start-ups?

This article was originally published in Clinica

Executive Summary

For most new medtech companies, venture capital appears to be the most obvious way of garnering the necessary start-up funds to build a solid business. However, according to Dr Ian Cumming, CEO of Welsh start-up Ovasort, a company focused on developing high-volume cell separation technology, this is not always the best way to lever a start-up into financial growth. Ovasort itself is an example of a firm that has prospered without the crutch of venture capital. The company, located at Cardiff University's MediCentre for burgeoning medical and healthcare companies, is "a company without a product" according to Dr Cumming. Ovasort owns a patent for assisting with the process of discovering proteins on the surfaces of cells. The company is currently using this patent to develop a low-cost sperm separation kit for distinguishing between X- and Y-chromosome bearing cells for the artificial cattle insemination market and is also looking to diversify into the cancer research and diagnostics sector.

You may also be interested in...

PBA Announces New Leadership; Honest Company Names CFO; Beauty Executive News

Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.

Biden Aims For 200 Mil. More COVID Vaccine Doses As Nervous Europe Eyes Its Borders

Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.

Listerine, Tylenol Push J&J Consumer Health To 2020 Finish Line Against Pandemic Weight

Listerine mouthwash drove J&J’s oral care sales up 11.4% in the fourth quarter. Tylenol for adults was the star of its OTC drug business but weakness of children’s Tylenol products and other OTCs led to flat sales.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts